Company Overview
About DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a secure, scalable, and regulatory-compliant cloud environment where pharmaceutical companies, genomics labs, biobanks, health systems, and research institutions can store, analyze, and share multimodal biomedical data — including genomic sequences, clinical records, imaging, and real-world evidence. The platform is purpose-built for the data types, compliance requirements, and computational workloads unique to biomedical research and precision medicine development.
Business Model & Competitive Advantage
DNAnexus secured $200M in Series I financing led by Blackstone Growth in March 2022, with participation from Northpond Ventures, GV (Google Ventures), Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital. Total funding exceeds $300M. The platform stores over 65 petabytes of data — growing at 70% per year since 2015 — and serves more than 12,000 users across 48 countries. Customer penetration in the pharma industry is exceptional: seven of the top 10 global pharmaceutical companies and eight of the top 10 diagnostics companies rely on DNAnexus for their precision medicine workflows.
Competitive Landscape 2025–2026
In 2025, DNAnexus CEO Thomas Laur was named among the Top Healthcare Technology CEOs of the Year, and the company received recognition from Frost & Sullivan for leadership in precision health informatics. DNAnexus competes with AWS HealthLake, Microsoft Azure Genomics, and Terra (Verily/Broad Institute) for the cloud genomics market. Its differentiators include deep workflow automation capabilities via the WDL/CWL standards, robust access controls for population-scale biobanks, and its long track record serving the most data-sensitive research environments in life sciences.
Key Differentiators
Market Leader
DNAnexus is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare DNAnexus with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from DNAnexus? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim DNAnexus Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention DNAnexus vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →